logo-loader

Herbalife says recently held talks about a deal to take the firm private, launches share tender offer.

Last updated: 09:06 21 Aug 2017 EDT, First published: 04:06 21 Aug 2017 EDT

Healthy products
Herbalife added that it has commenced a modified Dutch auction self-tender offer to buy up to US$600mln of its own shares for cash

Herbalife Ltd. (NYSE:HLF) saw its shares jump 8% higher in pre-market trading after the health products distributor confirmed it recently held talks about a transaction to take the firm private and said it is to launch a share tender offer.

The NYSE-listed firm said the talks with an unnamed prospective financial investor anout taking the company private have now ended.

In a statement, Herbalife said:"While these conversations were formally terminated on August 16, 2017, because these discussions contemplated the possibility of the Company being taken private, the Board of Directors decided to provide tendering shareholders with some protection in the event the Company is taken private within two years resulting in remaining shareholders possibly receiving a higher price than paid in the self-tender.”

The group added that it has commenced a modified Dutch auction self-tender offer to buy up to US$600mln of its own shares for cash.

Shareholders who tender their shares will be paid no less than US$60 a share and no more than US$68, and will receive a contingency value right as part of the deal which would give them the right to a contingent cash payment if the company is taken private.

The company said, in connection with the tender offer, that investor Carl Icahn has agreed not to increase his stake in the company above 50% unless he has agreed to buy 100% of the shares. Icahn will not be participating in the tender offer.

In pre-market trading, Herbalife shares – which have gained 29% in the year to date, were 8.2% higher at US$67.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 7 minutes ago